User:Alex12271/黃炳鏐

Dr. WONG Bing Lou, who is an American scientist of Chinese descent. Dr. Wong currently serves as the Chairman of the Scientific Committee of the department of Applied Biology and Chemical Technology at Hong Kong Polytechnic University and is Adjunct Professor of the School of Life Science of Chinese University of Hong Kong.

Dr. Wong is also the Founder and Chairman of Bing BioTech Limited. He is responsible for providing scientific advice and developing innovative enzyme-based therapeutic products for the global markets. He has 50 years of experience in enzyme technology, particularly in the development of protein and enzyme therapeutics in the biotechnology industry. He has successfully developed antidotes for certain cancer drugs as well as being the leading scientist of the very first scale up 𝛼-1 interferon preparation in the 1980s. During his tenure as Acting Director at the New England Enzyme Center and Associate Professor at Tufts Medical School in Boston, Dr. Wong was responsible for the preparation of hundreds of biologics. He is an expert in enzyme technology, bioprocess, fermentation, protein purification and protein engineering.

In 1992, the Executive Yuan of the Republic of China named him "Model of Overseas Chinese Young Entrepreneur". In 2001, Bunker Hill Community College of Boston, Massachusetts awarded Dr. Wong a President’s Distinguished Service Award for his extraordinary commitment for higher education in the Boston Asian community.

From 2007 to 2018, Dr. Wong was the Chief Technology Officer of New A Innovation Limited.

From 2002 to the present, Dr. Wong has been a Director of Advantek Biologics (HK) Limited. He worked on a novel process for purifying Immunoglobin G from human plasma as well as developing an enzyme Chondroitinase ABC that is used for cleaning up the nerve grafting for surgical purposes. This enzyme is also useful for treatment for disc herniation.

During his tenure as Acting Director at the New England Enzyme Center and Associate Professor at Tufts Medical School of Boston, Dr. Wong was responsible for the preparation of hundreds of biologics. Dr. Wong was the co-founder of Biopure® Corporation (NASDAQ: BPUR), where he served as Chief Technology Officer and Senior Vice President. At Biopure®, Dr. Wong was responsible for the development of Cephalosporin antibiotics and Hemoglobin-based oxygen carriers (artificial blood): Hemopure® and Oxyglobin®, as well as strategic business ventures in the US and the Far East. Dr. Wong also holds multiple patents and been a licensor to a number of world-leading companies such as Roche (SWX: RO) and Teva (NASDAQ: TEVA).

In the mid-1970s, Dr. Wong successfully isolated two important enzymes from calf liver for accelerating alcohol metabolism, namely Alcohol Dehydrogenase (“ADH”) and Aldehyde Dehydrogenase (“ALDH”). These two enzymes were further purified and the in-vitro assays proved that the corresponding enzymatic activity is highly potent, and when combined in the correct molar ratios could potentially be used to enhance the degradation of alcohol in the human body both for frequent alcohol drinkers as well as alleviating hangover symptoms. BBT has been established to develop and commercialize these enzymes. Furthermore, BBT intends to develop and commercialize a probiotic that can be used to treat non-alcoholic fatty liver disease (“NAFLD”) as well as alcoholic liver disease (“ALD”).

Although BBT is a newly established research platform company, its research team has substantial  expertise in enzyme and biologics preparations. For example, Dr. Wong developed an enzyme antidote, carboxypeptidases G1, for clearance of excess methotrexate (a chemotherapy agent used to treat cancer). Another achievement was the manufacturing of high quality and high purity urease from Jack beans for Blackman Diagnostic, for a reagent for determination of blood urea nitrogen (BUN). In addition to those developments, the founder developed an enzymatic processing system for converting cephalosporin-C to 7-aminocephalosporanic acid (7-ACA). Nowadays, most of the cephalosporin-C antibiotic fermentation manufacturing facilities are using this enzymatic processing system.

For biologics, the founder and his team had prepared the very first rDNA batch of alpha interferon and also developed an artificial blood, known as Hemopure for emergency blood transfusion and enhancing cancer chemotherapies. Hemopure has been approved for use in South Africa and Russia.